Home NDC 68462-495-30 deferasirox
Product NDC 68462-495
Requested package NDC 68462-495-30
11-digit product format 684620495
Labeler code 68462
Product ID 68462-495_1eeaa820-150f-484b-b5b0-f57415f49083
Type HUMAN PRESCRIPTION DRUG
Nonproprietary name deferasirox
Dosage form TABLET, FOR SUSPENSION
Route ORAL
Labeler Glenmark Pharmaceuticals Inc., USA
Application ANDA209433
Marketing category ANDA
Marketing start 2020-01-06
Substance DEFERASIROX
Active strength 250 mg/1
Pharmacologic classes Cytochrome P450 1A2 Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A4 Inducers [MoA], Iron Chelating Activity [MoA], Iron Chelator [EPC]
NDC exclude flag No
Listing certified through 2027-12-31
Current FDA listing Yes
Observed NDC auxiliary status history# This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.
Historic NDC status page 1 of 1 · 2 matching rows.
View current auxiliary records. · View the auxiliary file history.
Captured / source date, Dataset, Scope table Captured / source date Dataset Scope Product NDC Package NDC Code Status Reporting period Archive Snapshot Source SHA-256 2025-12-14 17:58 UTC · source 2025-12-05 excluded package package 68462-495 68462-495-30 D Discontinued by firm excluded / ndc_excluded.zip d630ba8d3edf…732f749b63fb…2025-08-27 00:01 UTC · source 2025-08-26 excluded package package 68462-495 68462-495-30 D Discontinued by firm excluded / ndc_excluded.zip f5e01cc5f278…a2eaf40c39c3…
Source provenance: Browse the complete Orange Book source catalog · source snapshot 45 .
Orange Book products# Current product rows page 1 of 1 · 3 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date A209433-001 DEFERASIROX DEFERASIROX 125MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 A209433-002 DEFERASIROX DEFERASIROX 250MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 A209433-003 DEFERASIROX DEFERASIROX 500MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06
Therapeutic equivalence codes# Current TE-code rows page 1 of 1 · 3 matching rows.
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 1 of 4 · 123 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-11-14 07:37:17 2026-10 A209433-001 DEFERASIROX 125MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 A209433-002 DEFERASIROX 250MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 A209433-003 DEFERASIROX 500MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 d4dbc9d85df4…2026-10-15 13:18:30 2026-09 A209433-001 DEFERASIROX 125MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 c2088c7a36db…2026-10-15 13:18:30 2026-09 A209433-002 DEFERASIROX 250MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 c2088c7a36db…2026-10-15 13:18:30 2026-09 A209433-003 DEFERASIROX 500MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 c2088c7a36db…2026-09-14 22:38:34 2026-08 A209433-001 DEFERASIROX 125MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 84e616aacf4f…2026-09-14 22:38:34 2026-08 A209433-002 DEFERASIROX 250MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 84e616aacf4f…2026-09-14 22:38:34 2026-08 A209433-003 DEFERASIROX 500MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 84e616aacf4f…2026-08-18 06:07:40 2026-07 A209433-001 DEFERASIROX 125MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 caaa826d4ba7…2026-08-18 06:07:40 2026-07 A209433-002 DEFERASIROX 250MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 caaa826d4ba7…2026-08-18 06:07:40 2026-07 A209433-003 DEFERASIROX 500MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 A209433-001 DEFERASIROX 125MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 A209433-002 DEFERASIROX 250MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 A209433-003 DEFERASIROX 500MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 A209433-001 DEFERASIROX 125MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 A209433-002 DEFERASIROX 250MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 A209433-003 DEFERASIROX 500MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 A209433-001 DEFERASIROX 125MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 A209433-002 DEFERASIROX 250MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 A209433-003 DEFERASIROX 500MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 A209433-001 DEFERASIROX 125MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 A209433-002 DEFERASIROX 250MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 A209433-003 DEFERASIROX 500MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 A209433-001 DEFERASIROX 125MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 A209433-002 DEFERASIROX 250MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 A209433-003 DEFERASIROX 500MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 A209433-001 DEFERASIROX 125MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 A209433-002 DEFERASIROX 250MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 A209433-003 DEFERASIROX 500MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 03ed91905a0d…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 A209433-001 DEFERASIROX 125MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 2680178bc6a6…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 A209433-002 DEFERASIROX 250MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 2680178bc6a6…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 A209433-003 DEFERASIROX 500MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 2680178bc6a6…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 A209433-001 DEFERASIROX 125MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 5bbf6a4d5a75…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 A209433-002 DEFERASIROX 250MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 5bbf6a4d5a75…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 A209433-003 DEFERASIROX 500MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 5bbf6a4d5a75…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 A209433-001 DEFERASIROX 125MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 d8e5a09893c0…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 A209433-002 DEFERASIROX 250MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 d8e5a09893c0…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 A209433-003 DEFERASIROX 500MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 d8e5a09893c0…2024-10-29 15:01 UTC 2024-10 A209433-001 DEFERASIROX 125MG TABLET, FOR SUSPENSION / ORAL AB 2020-01-06 d06236e962d9…
Observed Orange Book normalized TE history# Normalized TE history page 1 of 4 · 123 observed states.
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
Finished product Yes
Brand name base deferasirox
Listing expiration 2027-12-31 Active Ingredients# Ingredient, Strength table Ingredient Strength DEFERASIROX 250 mg/1
Harmonized UNII identifiers# UNII identifiers page 1 of 1 · 1 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination V8G4MOF2V9 Internal UNII lookup
Harmonized RxCUI identifiers# RxCUI identifiers page 1 of 1 · 3 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination 597768 Internal RxNorm lookup 597770 Internal RxNorm lookup 597772 Internal RxNorm lookup
Harmonized SPL set identifiers# SPL set identifiers page 1 of 1 · 1 matching rows.
DailyMed Product Concepts# DailyMed Package Descriptions# Package NDC, Product, Description table Package NDC Product Description Form Quantity Strength SPL version 68462-495-30 deferasirox 30 in 1 BOTTLE TABLET, FOR SUSPENSION 30 5 68462-495-90 deferasirox 90 in 1 BOTTLE TABLET, FOR SUSPENSION 90 5
DailyMed Dashboard NDC Coverage# NDC, Dashboard title, SPL version table NDC Dashboard title SPL version Validation Dashboard ZIP 68462-495 DEFERASIROX TABLET, FOR SUSPENSION [GLENMARK PHARMACEUTICALS INC., USA] 5 Current NDC, Legacy NDC, 2 package rows 20241127_59f1d3fb-5bdb-4261-8557-9a4bde8b3c1c.zip
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
DailyMed RxNorm Mappings# Packages# Package NDC, 11-digit format, Description table Package NDC 11-digit format Description Marketing start Marketing end Sample Exclude flag Status 68462-495-30 68462049530 30 TABLET, FOR SUSPENSION in 1 BOTTLE (68462-495-30) 2020-01-06 0000-00-00 No No Current